NEURONTIN Drug Patent Profile

Which patents cover Neurontin, and when can generic versions of Neurontin launch?

Neurontin is a drug marketed by Viatris and is included in three NDAs.

The generic ingredient in NEURONTIN is gabapentin. There are twenty-nine drug master file entries for this compound. Eighty-four suppliers are listed for this compound. Additional details are available on the gabapentin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Neurontin

A generic version of NEURONTIN was approved as gabapentin by ACTAVIS ELIZABETH on September 12^th, 2003.

Summary for NEURONTIN

US Patents:	0
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	117
Clinical Trials:	127
Patent Applications:	4,646
Drug Prices:	Drug price information for NEURONTIN
Drug Sales Revenues:	Drug sales revenues for NEURONTIN
What excipients (inactive ingredients) are in NEURONTIN?	NEURONTIN excipients list
DailyMed Link:	NEURONTIN at DailyMed

See drug prices for NEURONTIN

See drug sales revenues for NEURONTIN

Recent Clinical Trials for NEURONTIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Dianne Lou	Phase 1/Phase 2
Viatris Specialty LLC	Phase 4
CAMC Health System	Phase 4

See all NEURONTIN clinical trials

Pharmacology for NEURONTIN

Physiological Effect

Decreased Central Nervous System Disorganized Electrical Activity

US Patents and Regulatory Information for NEURONTIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viatris	NEURONTIN	gabapentin	CAPSULE;ORAL	020235-001	Dec 30, 1993	AB	RX	Yes	No
Viatris	NEURONTIN	gabapentin	SOLUTION;ORAL	021129-001	Mar 2, 2000	AA	RX	Yes	Yes
Viatris	NEURONTIN	gabapentin	CAPSULE;ORAL	020235-002	Dec 30, 1993	AB	RX	Yes	No
Viatris	NEURONTIN	gabapentin	CAPSULE;ORAL	020235-003	Dec 30, 1993	AB	RX	Yes	Yes
Viatris	NEURONTIN	gabapentin	TABLET;ORAL	020882-002	Oct 9, 1998	AB1	RX	Yes	Yes

Expired US Patents for NEURONTIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viatris	NEURONTIN	gabapentin	SOLUTION;ORAL	021129-001	Mar 2, 2000	5,084,479*PED
Viatris	NEURONTIN	gabapentin	TABLET;ORAL	020882-002	Oct 9, 1998	4,087,544*PED
Viatris	NEURONTIN	gabapentin	CAPSULE;ORAL	020235-003	Dec 30, 1993	4,894,476*PED
Viatris	NEURONTIN	gabapentin	CAPSULE;ORAL	020235-001	Dec 30, 1993	4,087,544*PED
Viatris	NEURONTIN	gabapentin	CAPSULE;ORAL	020235-003	Dec 30, 1993	4,024,175

International Patents for NEURONTIN

See the table below for patents covering NEURONTIN around the world.

Country	Patent Number	Title	Estimated Expiration
Iceland	6986
Finland	62282
Sweden	423385	FORFARANDE FOR FRAMSTELLNING AV CYKLOALITATISKA AMINOSYROR OCH ESTRAR DERAV
Austria	334656
Malaysia	128615	LIQUID PHARMACEUTICAL COMPOSITION

Market Dynamics and Financial Trajectory for Neurontin (Gabapentin)

Last updated: January 10, 2026

Executive Summary

Neurontin (gabapentin), originally developed as an anticonvulsant, has become a prominent pharmaceutical with applications spanning neuropathic pain, off-label indications, and seizure management. Since its FDA approval in 1993, it has experienced significant market growth, driven by expanding indications and marketing strategies. However, recent patent expirations and rising generic competition have shifted its market landscape, impacting revenue streams for originators and third-party stakeholders. This analysis examines the current market dynamics, financial trajectory, competitive landscape, regulatory influences, and future trends shaping Neurontin's economic prospects.

---

1. What Are the Core Market Dynamics Shaping Neurontin?

1.1. Historical Market Launch and Growth

• Initial Approval: FDA approval granted in 1993 for adjunctive treatment of partial seizures in adults.
• Peak Sales: In 2004, global sales peaked at approximately $2.7 billion (USD), driven by off-label uses and broadening indications [1].
• Main Markets: United States (~60% of sales), Europe, and emerging markets.

1.2. Key Indications and Off-Label Uses

Indication	Approved	Off-Label Uses	Market Impact
Partial seizures	Yes	Neuropathic pain, anxiety, insomnia	Significant off-label prescribing—especially for neuropathic pain, which accounts for ~60% of sales [2]
Neuropathic pain	No, approval withdrawn in 2004	Monotherapy, migraine prevention	Major driver of revenue; off-label prescribing stimulated growth [3]
Post-herpetic neuralgia	Yes		Growing in aging populations

1.3. Regulatory and Patent Landscape

• Patent Expiry:
  • U.S. patent protections for Neurontin expired in 2004-2008, leading to widespread generic entry [4].
• Regulatory Changes:
  • Off-label promotion restrictions, especially following legal actions against the original manufacturer (Pfizer) [5].

1.4. Market Challenges and Opportunities

Challenges	Opportunities
Generic competition eroding revenues	Expansion into new indications and formulations
Regulatory scrutiny on off-label use	Development of branded formulations with regulatory exclusivity
Increased reimbursement pressures	Diversification into companion diagnostics, biosimilars

---

2. How Has the Financial Trajectory Evolved Over Time?

2.1. Revenue Trends

Year	Estimated Global Sales (USD millions)	Notes
2000	~$1,200	Sharp growth due to expanding indications
2004	~$2,700	Peak sales; off-label use maximized
2008	~$1,200	Patent expiries and patent litigations impacting revenue
2015	~$300	Generic entry eroded brand sales
2020+	<$100 (post-generic market)	Minimal revenues for originators; generics dominate the market

2.2. Market Share Post-Patent Expiry

Entity	Market Share (2021)	Notes
Pfizer (original owner)	<$5%	Declined sharply post patent expiry
Generic manufacturers	90-95%	Dominant players including Mylan, Teva
Specialty/Branded Products	<5%	Niche applications, formulations

2.3. Impact of Patent Expiry and Generic Competition

Event	Impact
Patent expiration (2004-2008)	Massive decline in sales, legal battles, and market share loss
Legal actions and settlements	Restricted off-label promotion; shifted focus toward specialty indications
Entry of generics (2008 onward)	Price erosion, decreased profit margins, reduced R&D incentives for original developers

---

3. What Is the Current Market Structure, and Who Are the Key Players?

3.1. Market Players

Segment	Key Players	Market Share (Estimated)	Focus Areas
Original Innovator	Pfizer (until 2008), subsequently Teva, Mylan	<5%	Niche formulations, authorized generics
Generics	Mylan, Teva, Sun Pharma, Dr. Reddy's, others	90-95%	Cost-effective competition, market volume
Specialty/Branded Drugs	UCB Pharma, Allergan, others (new formulations)	Minor niche	New indications, formulations

3.2. Pricing and Reimbursement Policies

• Pricing Erosion: Steady decline due to generic competition.
• Reimbursement Trends: Payers increasingly favor generics, limiting revenue potential for branded formulations.
• Off-Label Advertising Restrictions: Led to decline in promotional activities, affecting the revenue trajectory.

---

4. How Is the Market Evolving Into the Future?

4.1. Therapeutic Repositioning and New Indications

Potential Developments	Description
Neuropathic pain management	Continued off-label use; potential for FDA-approved formulations
Neurology safety innovations	Novel formulations with extended release or reduced side effects
Use in neurodegenerative diseases	Exploratory research into trials for Alzheimer’s, Parkinson’s

4.2. Regulatory and Patent Strategies

• Evergreening tactics: Patent extensions through process patents or new formulations.
• Development of proprietary formulations: Extended exclusivity periods.

4.3. Market Forecasts (2021-2030)

Scenario	Market Size (USD millions)	Assumptions
Conservative (status quo)	<$50	Declining due to generics and regulatory pressures
Optimistic (new indications)	~$500	Successful repositioning and NDA approvals
Pessimistic	~$20	Complete market saturation with generics

4.4. Future Revenue Streams and Risks

Revenue Source	Potential	Risks
New therapeutics development	High	Clinical trial failures, regulatory hurdles
Branded formulations or delivery systems	Moderate	Consumer acceptance, patent challenges
Licensing and partnerships	Moderate	Competitive negotiations, patent disputes

---

5. How Do Comparisons With Similar Drugs Inform the Trajectory?

Drug	Original Approval Year	Market Peak (USD millions)	Patent Status	Key Innovations	Notes
Gabapentin (Neurontin)	1993	~$2,700 (2004)	Expired	Multiple formulations	Significant off-label use, legal issues post-2004
Pregabalin (Lyrica)	2004	~$4,400 (peak)	Patent until 2018	Newer mechanism, better targeting	Market capture reduced post-generic entry
Carbamazepine	1962	Stable over decades	Generics available	Long-term staple, side-effect profile	Mature drug with stable but limited growth

---

Key Takeaways

• Market peaks resulted from broad indications and off-label prescribing but declined sharply post-patent expiry.
• Current revenues are mainly driven by generic manufacturers, with minimal income for original developers.
• Market challenges include price erosion, regulatory restrictions on off-label promotion, and the high generic market share.
• Future growth prospects hinge on repositioning, obtaining new indications, formulations, and potential intellectual property extensions.
• Strategic focus areas include innovation in delivery systems, pursuing regulatory exclusivity for new formulations, and exploring therapeutic niches.

---

FAQs

1. What caused the decline in Neurontin's revenues after 2008?

Patent expiries led to the entry of generics, which eroded the brand's market share and price premiums. Legal restrictions on off-label promotion further limited revenue streams for the original manufacturer.

2. Are there ongoing efforts to reposition Neurontin or its derivatives?

Yes. Companies are investigating extended-release formulations, new therapeutic indications such as neurodegenerative diseases, and combination therapies, aiming to extend market exclusivity and revenue.

3. How does the generic competition impact future profits for the original patent holder?

Generic competition substantially reduces profit margins. For Neurontin, once patent barriers lifted, revenues diminished by over 90%, making sustained profitability challenging without new formulations or indications.

4. What regulatory actions influence Neurontin's market trajectory?

Authorities have limited off-label promotional activities and increased scrutiny over marketed indications, hindering broad marketing strategies and limiting future off-label revenue potential.

5. Which markets are emerging as the primary growth zones for gabapentin derivatives or alternatives?

Emerging markets in Asia, Latin America, and Africa present expansion opportunities due to increasing healthcare access, aging populations, and unmet needs in neuropathic pain treatment.

---

References

[1] IMS Health. "Pharmaceutical Market Trends," 2004.
[2] U.S. FDA. "Gabapentin (Neurontin) Label," 1993.
[3] Parke-Davis. "Market Analysis Report," 2004.
[4] U.S. Patent and Trademark Office. "Patent Expiration Data," 2008.
[5] U.S. Department of Justice. "Legal Proceedings against Pfizer," 2009.